Analyzing Bellerophon Therapeutics (NASDAQ:BLPH) and CytomX Therapeutics (NASDAQ:CTMX)

Share on StockTwits

Bellerophon Therapeutics (NASDAQ:BLPH) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Valuation and Earnings

This table compares Bellerophon Therapeutics and CytomX Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bellerophon Therapeutics N/A N/A $2.81 million ($0.34) -1.25
CytomX Therapeutics $59.50 million 4.90 -$84.60 million ($2.03) -3.16

Bellerophon Therapeutics has higher earnings, but lower revenue than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bellerophon Therapeutics and CytomX Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bellerophon Therapeutics N/A -102.96% -42.26%
CytomX Therapeutics -163.18% -90.62% -23.58%

Risk & Volatility

Bellerophon Therapeutics has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Institutional & Insider Ownership

50.4% of Bellerophon Therapeutics shares are owned by institutional investors. Comparatively, 78.9% of CytomX Therapeutics shares are owned by institutional investors. 53.1% of Bellerophon Therapeutics shares are owned by company insiders. Comparatively, 6.3% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Bellerophon Therapeutics and CytomX Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bellerophon Therapeutics 0 0 2 0 3.00
CytomX Therapeutics 0 1 9 0 2.90

Bellerophon Therapeutics presently has a consensus price target of $2.50, suggesting a potential upside of 487.68%. CytomX Therapeutics has a consensus price target of $19.13, suggesting a potential upside of 197.90%. Given Bellerophon Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Bellerophon Therapeutics is more favorable than CytomX Therapeutics.

Summary

Bellerophon Therapeutics beats CytomX Therapeutics on 7 of the 13 factors compared between the two stocks.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Decreases Stake in National-Oilwell Varco, Inc.
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
CWM Advisors LLC Sells 287 Shares of Watts Water Technologies Inc
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 1,095 Shares of iShares Russell 1000 Value ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
James Investment Research Inc. Purchases 46,666 Shares of iShares MSCI South Korea ETF
PNM Resources Inc  Shares Sold by James Investment Research Inc.
PNM Resources Inc Shares Sold by James Investment Research Inc.
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc
James Investment Research Inc. Acquires 30,776 Shares of Radian Group Inc


© 2006-2020 Ticker Report